Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
A lot of news in two months. All aboard?
***KAST*** SILVER SPRINGS, NV / ACCESSWIRE / December 15, 2016 / Kasten, Inc. (KAST) announced today it has signed a term sheet to joint venture with Pettersson Adams Medical Research.
Pettersson is engaged in developing innovative health products utilizing unique and patented technologies. They have developed a technology designed to treat and reverse the plaques that accumulate in the brain thus enhancing the quality of life, the cognitive functions of the brain and improving overall brain health. The technology is centered and targeted on the delivery of compounds both transdermal and transintestinal. The technology developed by Pettersson not only treats the symptoms but also addresses the environment in the body that causes the symptoms.
Plaques in the brain can not only lead to brain abnormality but death. Intracranial stenosis is a narrowing of an artery inside the brain. A buildup of plaque (atherosclerosis) inside the artery wall reduces blood flow to the brain. Atherosclerosis that is severe enough to cause symptoms carries a high risk of stroke and can lead to brain damage and death. In addition, one of the hallmarks of Alzheimer's disease is the accumulation of amyloid plaques between nerve cells (neurons) in the brain. The technology developed by Pettersson to treat and reverse plaques that accumulate in the brain has the potential to save millions of lives and provide hope to those that are suffering with Alzheimer's disease and dementia.
Both parties have 45 days to conduct and complete due diligence. Upon successful due diligence testing, Kasten believes it can create and maintain a successful marketing program to introduce the technology to the marketplace. The companies are also exploring a distribution agreement.
Kasten, Inc. is a biopharmaceutical company focused on the acquisition, development, and commercialization of medical therapies designed to prevent and/or treat serious medical conditions. Kasten is principally focused on delivering solutions to those medical conditions for which the care pathway is burdened by high morbidity, mortality, and cost.
CONTACT:
Kasten, Inc.
702-860-2407
pr@kastenbiopharma.com
SOURCE: Kasten, Inc.
***KAST***SILVER SPRINGS, NV / ACCESSWIRE / December 15, 2016 / Kasten, Inc. (KAST) announced today it has signed a term sheet to joint venture with Pettersson Adams Medical Research.
Pettersson is engaged in developing innovative health products utilizing unique and patented technologies. They have developed a technology designed to treat and reverse the plaques that accumulate in the brain thus enhancing the quality of life, the cognitive functions of the brain and improving overall brain health. The technology is centered and targeted on the delivery of compounds both transdermal and transintestinal. The technology developed by Pettersson not only treats the symptoms but also addresses the environment in the body that causes the symptoms.
Plaques in the brain can not only lead to brain abnormality but death. Intracranial stenosis is a narrowing of an artery inside the brain. A buildup of plaque (atherosclerosis) inside the artery wall reduces blood flow to the brain. Atherosclerosis that is severe enough to cause symptoms carries a high risk of stroke and can lead to brain damage and death. In addition, one of the hallmarks of Alzheimer's disease is the accumulation of amyloid plaques between nerve cells (neurons) in the brain. The technology developed by Pettersson to treat and reverse plaques that accumulate in the brain has the potential to save millions of lives and provide hope to those that are suffering with Alzheimer's disease and dementia.
Both parties have 45 days to conduct and complete due diligence. Upon successful due diligence testing, Kasten believes it can create and maintain a successful marketing program to introduce the technology to the marketplace. The companies are also exploring a distribution agreement.
Kasten, Inc. is a biopharmaceutical company focused on the acquisition, development, and commercialization of medical therapies designed to prevent and/or treat serious medical conditions. Kasten is principally focused on delivering solutions to those medical conditions for which the care pathway is burdened by high morbidity, mortality, and cost.
CONTACT:
Kasten, Inc.
702-860-2407
pr@kastenbiopharma.com
SOURCE: Kasten, Inc.
KAST about to explode!
KAST about to explode!
Kasten, Inc. Announces Signed Joint Venture Agreement with Dakota Life Sciences
SILVER SPRINGS, NV / ACCESSWIRE / January 3, 2017 / Kasten, Inc. (OTC PINK: KAST) announced today it has signed a Joint Venture agreement with Thru Pharma LLC dba DAKOTA Life Sciences for the purpose of promoting the development and marketing of Site Specific Penetration Technology (SSPT™ ) biopharmaceutical products.
Dakota Life Sciences is engaged in developing innovative health products utilizing SSPT™ technologies. These products include but are not limited to Thin Nail® (OTC First Aid Nail Antifungal), Symphony OTC First Aid Antibiotic, ThinNail® RX Topical Antifungal, Symphony ™ RX Topical Antibiotic, Reserve ™ Rx Line of Topical Antibiotics and an R&D pipeline of wound care and dermatology products, as well as genomics-based companion diagnostics.
Under the terms of the Joint Venture Agreement, both parties will have equal ownership rights. “This new joint venture is uniquely positioned to optimize the development of DAKOTA’s biopharmaceutical product line. Together we will launch their portfolio of products to the market place. This JV further compliments our roll-up strategy of developing and commercializing innovative medical solutions,” stated Jose Delgado, CEO of Kasten, Inc.
DAKOTA Life Sciences is a leading anti-infectives private pharmaceutical Company with award-winning products designed to provide the highest efficacy for global patients at high risk of suffering from dangerous microbial and fungal infections.
Kasten, Inc. is a biopharmaceutical company focused on the acquisition, development, and commercialization of medical therapies designed to prevent and/or treat serious medical conditions. Kasten is principally focused on delivering solutions to those medical conditions for which the care pathway is burdened by high morbidity, mortality, and cost.
CONTACT:
Kasten, Inc.
702-860-2407
pr@kastenbiopharma.com
SOURCE: Kasten, Inc.
ReleaseID: 452045
Kasten, Inc. Announces Signed Joint Venture Agreement with Dakota Life Sciences
SILVER SPRINGS, NV / ACCESSWIRE / January 3, 2017 / Kasten, Inc. (OTC PINK: KAST) announced today it has signed a Joint Venture agreement with Thru Pharma LLC dba DAKOTA Life Sciences for the purpose of promoting the development and marketing of Site Specific Penetration Technology (SSPT™ ) biopharmaceutical products.
Dakota Life Sciences is engaged in developing innovative health products utilizing SSPT™ technologies. These products include but are not limited to Thin Nail® (OTC First Aid Nail Antifungal), Symphony OTC First Aid Antibiotic, ThinNail® RX Topical Antifungal, Symphony ™ RX Topical Antibiotic, Reserve ™ Rx Line of Topical Antibiotics and an R&D pipeline of wound care and dermatology products, as well as genomics-based companion diagnostics.
Under the terms of the Joint Venture Agreement, both parties will have equal ownership rights. “This new joint venture is uniquely positioned to optimize the development of DAKOTA’s biopharmaceutical product line. Together we will launch their portfolio of products to the market place. This JV further compliments our roll-up strategy of developing and commercializing innovative medical solutions,” stated Jose Delgado, CEO of Kasten, Inc.
DAKOTA Life Sciences is a leading anti-infectives private pharmaceutical Company with award-winning products designed to provide the highest efficacy for global patients at high risk of suffering from dangerous microbial and fungal infections.
Kasten, Inc. is a biopharmaceutical company focused on the acquisition, development, and commercialization of medical therapies designed to prevent and/or treat serious medical conditions. Kasten is principally focused on delivering solutions to those medical conditions for which the care pathway is burdened by high morbidity, mortality, and cost.
CONTACT:
Kasten, Inc.
702-860-2407
pr@kastenbiopharma.com
SOURCE: Kasten, Inc.
ReleaseID: 452045
Kasten, Inc. Announces LOI to Acquire Formulas for Alzheimers Disease and E.D.
Posted: Dec 02, 2016 5:26 PM PET
Updated: Dec 02, 2016 5:26 PM PET
SILVER SPRINGS, NV / ACCESSWIRE / December 2, 2016 / Kasten, Inc. (KAST) announced today it has signed a letter of intent (LOI) to acquire formulas for Alzheimer’s Disease and Erectile Dysfunction. The acquisition of the formulas will launch the Company into a broader portfolio of treatments for medical conditions outside of immediate urgent care.
“We are committed to providing solutions to medical conditions to extend quality of life. Alzheimer’s disease is the only leading cause of death in the U.S. that has no therapies to prevent, cure or slow its progression. At $236 billion a year, it is also the most expensive disease in the U.S. We have an opportunity to make a difference for millions of people suffering daily,” stated Jose Delgado, CEO of Kasten, Inc.
The Company is currently negotiating the terms of the definitive agreement with Gulf Coast Pharmaceutical, Inc. and is expected to close on the asset purchase within the next thirty days.
The Company also announced the resignation of Executive Chairman Michael Handley. “We are thankful to Mike for his assistance over these past couple of months as we now turn our sights onto raising the funds required to implement the opportunities we have put in place. We look forward to continuing to work with Mike and CHD to advance our directives,” stated Jose Delgado, CEO of Kasten, Inc.
Kasten, Inc. is a biopharmaceutical company focused on the acquisition, development, and commercialization of medical therapies designed to prevent and/or treat serious medical conditions. Kasten is principally focused on delivering solutions to those medical conditions for which the care pathway is burdened by high morbidity, mortality, and cost.
CONTACT:
Kasten, Inc.
702-860-2407
pr@kastenbiopharma.com
SOURCE: Kasten, Inc.
Kasten, Inc. Announces LOI to Acquire Formulas for Alzheimers Disease and E.D.
Posted: Dec 02, 2016 5:26 PM PET
Updated: Dec 02, 2016 5:26 PM PET
SILVER SPRINGS, NV / ACCESSWIRE / December 2, 2016 / Kasten, Inc. (KAST) announced today it has signed a letter of intent (LOI) to acquire formulas for Alzheimer’s Disease and Erectile Dysfunction. The acquisition of the formulas will launch the Company into a broader portfolio of treatments for medical conditions outside of immediate urgent care.
“We are committed to providing solutions to medical conditions to extend quality of life. Alzheimer’s disease is the only leading cause of death in the U.S. that has no therapies to prevent, cure or slow its progression. At $236 billion a year, it is also the most expensive disease in the U.S. We have an opportunity to make a difference for millions of people suffering daily,” stated Jose Delgado, CEO of Kasten, Inc.
The Company is currently negotiating the terms of the definitive agreement with Gulf Coast Pharmaceutical, Inc. and is expected to close on the asset purchase within the next thirty days.
The Company also announced the resignation of Executive Chairman Michael Handley. “We are thankful to Mike for his assistance over these past couple of months as we now turn our sights onto raising the funds required to implement the opportunities we have put in place. We look forward to continuing to work with Mike and CHD to advance our directives,” stated Jose Delgado, CEO of Kasten, Inc.
Kasten, Inc. is a biopharmaceutical company focused on the acquisition, development, and commercialization of medical therapies designed to prevent and/or treat serious medical conditions. Kasten is principally focused on delivering solutions to those medical conditions for which the care pathway is burdened by high morbidity, mortality, and cost.
CONTACT:
Kasten, Inc.
702-860-2407
pr@kastenbiopharma.com
SOURCE: Kasten, Inc.
Kasten, Inc. Announces Agreement for Sublicensing of Novel Formulation of Bactracin for Drug Resistant Bacteria
Nov 14, 2016
OTC Disclosure & News Service
Silver Springs, NV -
Company provides information regarding a Sublicensing Agreement for Novel Formulations of Bactracin for the Mitigation or Treatment of Highly Drug Resistant Bacterial Infections
Kasten, Inc. (OTC PINK: KAST) is a biopharmaceutical company focused on the acquisition, development, and commercialization of medical therapies designed to prevent and/or treat serious conditions arising in the hospital and adjacent clinical settings. Kasten is principally focused on delivering solutions to those clinical wards in which the care pathway is burdened by high morbidity, mortality, and cost.
One particular causative be 64% more likely to die than people with a non-resistant form of the infection. GlobalData forecasts that the MRSA treatment market will grow at a compounded annual growth rate of 3.4% over the next few years to reach $3.5 billion by 2019.
Present antibiotic topical ointments used to prevent or treat Staphylococcus aureus, which often contain bacitracin as an active antimicrobial ingredient, are not effective against hyper-resistant MRSA strains, such as USA300. These strains are in fact highly prevalent in the community and current antibiotic ointments may actually enrich the population of hyper-resistant MRSA. New strategies are needed to control emerging resistant pathogenic bacteria.
Intellectually property has been developed regarding an antimicrobial formulation that significantly potentiates the activity of bacitracin by using alkyl gallates, a group of antioxidants that are currently utilized as food preservatives. The combination of agent of high morbidity and mortality in the hospital setting is drug resistant Staphylococcus aureus. In particular, methicillin-resistant S. aureus (MRSA) is responsible for, according to the CDC, over 80,000 invasive infections and 11,285 related deaths occur every year in the U.S. alone. In fact, people with MRSA are estimated to bacitracin with particular alkyl gallates resulted in up to 1,000,000-fold increase in bactericidal activity against hyper-resistant MRSA strain USA300 and other multidrug-resistant human clinical isolates. The intellectual property and data has been sublicensed by Kasten and will be developed for use for the prevention and treatment of drug resistant bacterial infections.
"Kasten is excited to acquire a license to this potential life-saving therapy for MRSA infections," states Kasten CEO, Jose Delgado. "This transaction demonstrates Kasten's commitment to acquiring and developing new therapies for the acute care setting that save lives and decrease costs in hospitals."
Forward-Looking Statements - This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that could cause future results to differ materially from the forward-looking statements. You should consider these factors in evaluating the statements herein, and not rely on such statements. The forward-looking statements in this release are made as of the date hereof and Kasten, Inc. undertakes no obligation to update such statements.
CONTACT:
Kasten, Inc.
702-860-2407
pr@kastenbiopharma.com
SOURCE: Kasten, Inc.
Kasten, Inc. Announces Agreement for Sublicensing of Novel Formulation of Bactracin for Drug Resistant Bacteria
Nov 14, 2016
OTC Disclosure & News Service
Silver Springs, NV -
Company provides information regarding a Sublicensing Agreement for Novel Formulations of Bactracin for the Mitigation or Treatment of Highly Drug Resistant Bacterial Infections
Kasten, Inc. (OTC PINK: KAST) is a biopharmaceutical company focused on the acquisition, development, and commercialization of medical therapies designed to prevent and/or treat serious conditions arising in the hospital and adjacent clinical settings. Kasten is principally focused on delivering solutions to those clinical wards in which the care pathway is burdened by high morbidity, mortality, and cost.
One particular causative be 64% more likely to die than people with a non-resistant form of the infection. GlobalData forecasts that the MRSA treatment market will grow at a compounded annual growth rate of 3.4% over the next few years to reach $3.5 billion by 2019.
Present antibiotic topical ointments used to prevent or treat Staphylococcus aureus, which often contain bacitracin as an active antimicrobial ingredient, are not effective against hyper-resistant MRSA strains, such as USA300. These strains are in fact highly prevalent in the community and current antibiotic ointments may actually enrich the population of hyper-resistant MRSA. New strategies are needed to control emerging resistant pathogenic bacteria.
Intellectually property has been developed regarding an antimicrobial formulation that significantly potentiates the activity of bacitracin by using alkyl gallates, a group of antioxidants that are currently utilized as food preservatives. The combination of agent of high morbidity and mortality in the hospital setting is drug resistant Staphylococcus aureus. In particular, methicillin-resistant S. aureus (MRSA) is responsible for, according to the CDC, over 80,000 invasive infections and 11,285 related deaths occur every year in the U.S. alone. In fact, people with MRSA are estimated to bacitracin with particular alkyl gallates resulted in up to 1,000,000-fold increase in bactericidal activity against hyper-resistant MRSA strain USA300 and other multidrug-resistant human clinical isolates. The intellectual property and data has been sublicensed by Kasten and will be developed for use for the prevention and treatment of drug resistant bacterial infections.
"Kasten is excited to acquire a license to this potential life-saving therapy for MRSA infections," states Kasten CEO, Jose Delgado. "This transaction demonstrates Kasten's commitment to acquiring and developing new therapies for the acute care setting that save lives and decrease costs in hospitals."
Forward-Looking Statements - This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that could cause future results to differ materially from the forward-looking statements. You should consider these factors in evaluating the statements herein, and not rely on such statements. The forward-looking statements in this release are made as of the date hereof and Kasten, Inc. undertakes no obligation to update such statements.
CONTACT:
Kasten, Inc.
702-860-2407
pr@kastenbiopharma.com
SOURCE: Kasten, Inc.
Who is buying?
No volume today
No transfer = No deal and No deal = No liquidation
Bondholders could vote for something they think gonna happen but, again:
No transfer = No deal and No deal = No liquidation
and then process back to zero
As i know no transfer of blocks yet. Seems peruvian authorities not approving it. So we will see a new delay
Fake orders. Shorters selling at bid to drop price
Filled. Thanks
No. Just buying to make a 50%. Trade it
Come on sellers. I am waiting here
I am back. Trying to buy again at .0018
Last time bought .0016 sold .0026 will see
It says: Ministry of Energy and Mines must approve transfer. Practically is the same. Minister appoints president of Perupetro
Cash raising. More money to us shareholders. This is undervalue
No transfer = No deal. Stock startng to surge again
Rally time?
I am back. Bought again at .0016 good luck to all
NITE with a big buy order at .0021
Somebody said: No transfer no deal. And that is right
Someone knows something. Why buy now?
Some buys at the ask today .0035
Lmao
Volumen today 1% of O/S
PUMA buying 1 million shares at .0022
Big buy 275k shares at .004
BPZ Chief Legal to Court on thursday. Again, something happening internally
Today's link
http://www.kccllc.net/bpz/document/1560016150825000000000001
Mmm check this guys. Page 8
http://investorshub.advfn.com/uimage/uploads/2015/8/21/bblorimage.jpg
Something happening internally. Company third motion to extend period (more time to file Chapter 11 Plan). New date october 23th
http://www.kccllc.net/bpz/document/1560016150820000000000002
Big buys today
Great news cha-ching! Confirmed, was not part of the deal
Remember all: Peruvian goverment has the last word. No authorization = no transfer of assets = no deal = new Chapter 11 process (auction or restructuring plan)